CASI PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities
CASI PHARMACEUTICALS, INC. (CASIF) reported Increase (Decrease) in Accrued Liabilities of $6.39 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-05-15
| Period end | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|
| 2025-12-31 | $6.39M 20-F · filed 2026-05-15 |
| 2024-12-31 | $1.55M 20-F · filed 2026-05-15 |
| 2023-12-31 | -$876.00K 20-F · filed 2026-05-15 |
| 2022-12-31 | -$912.00K 20-F · filed 2025-03-31 |
| 2021-12-31 | $2.30M 20-F · filed 2024-03-28 |
| 2020-12-31 | -$1.43M 20-F · filed 2023-04-26 |